大暑方过，中国各地迎来一年最热的时节，防治夏季感冒也要提上健康日程。急性上呼吸道感染主要由 病毒或细菌引起，影响鼻腔、咽部或喉部，流行病学研究表明，30-50岁成年人每年都会经历2-3次感 冒，与季节并无明显关联，全年发生。临床医学统计，夏季感冒比例约占全年感冒人数的18%，且夏季 感冒一般比其他季节持续时间更长。①② 坚持循证营养科学研究 开拓复合维矿健康获益领域 复合维生素矿物质制剂包括维生素A、维生素B6、维生素B12、维生素C、维生素D、维生素E和叶酸， 及微量元素锌、铁、硒、镁、铜等。多种微量营养素通过协同作用增强黏膜屏障、调控免疫细胞分化 （如T细胞）及抗炎反应。其生物利用度优于单一补充剂，如维生素D促进抗菌肽分泌、促进钙吸收； 维生素C保护中性粒细胞、促进铁吸收；锌调节Th细胞平衡等。这对营养状况普遍较差的老年人尤为重 要。 仅在中国，每年报告的流感样疾病约340万例，导致每年估计流感相关死亡人数高达8.8万例。所幸，循 证医学界又有简单易行的感冒防治措施正式公布。 近日，赫力昂|善存发起全球首个"复合维生素矿物质与急性上呼吸道感染"的真实世界研究成果发表于 《亚太临床营养学》专业期刊，是首个基 ...

Core Viewpoint - The training organized by the Xishui County Tobacco Monopoly Bureau aims to enhance grassroots governance efficiency and improve the level of "informationization" through the implementation of the "133" project [1] Group 1: Training Objectives and Content - The training focused on practical applications of the "Golden Leaf Five Wisdom" system, "Three-Line Collaboration" platform, and digital dashboard operation standards to improve work efficiency and process control capabilities [1] - Marketing personnel concentrated on the construction and application of digital scenarios, including marketing data dashboards, the "9233" mobile platform, and integrated modern terminals, to enhance the digital tool application capabilities of frontline staff [1] Group 2: Training Outcomes and Future Directions - The training was attended by over 20 participants, with 6 individuals sharing their experiences, and more than 10 feedback issues collected and addressed on-site [1] - The training effectively promoted the transition from "experience management" to "intelligent governance," with plans to further integrate the results of the "133" project into daily operations and enhance quality, efficiency, and skill levels through digital tools [1]

Core Insights - The fast-moving consumer goods (FMCG) industry is transitioning from a "traffic era" to a "value era" due to diminishing traffic dividends and increasing competition [1][5] - Tmall and Otaipu have introduced the "User Lifecycle Value (CLTV) Health - GAIN" assessment system to help brands navigate the challenges of stock competition [1][3] - The GAIN model evaluates brand health across four dimensions: Generate Demand, Audience Adaptation, Intensify Engagement, and Nurture Growth, with 12 core indicators [1][11] Market Challenges - The FMCG sector faces significant challenges as traditional growth models are strained by a shrinking customer acquisition landscape [5] - Brands are increasingly focusing on maximizing user lifecycle value (CLTV) to shift from one-time transactions to long-term value management [5][11] CLTV Operations - Various brands are exploring CLTV operations to achieve sustainable growth, emphasizing the importance of user lifecycle value [6][9] - High-end brands are targeting high-net-worth individuals by creating exclusive experiences and emotional connections to enhance loyalty and repurchase rates [7] - Efficacy-driven skincare brands are leveraging professional content and precise conversion strategies to build trust and drive user demand [8] GAIN Assessment Model - The GAIN model quantifies user value and helps brands identify growth opportunities by focusing on long-term value rather than one-time traffic [11][14] - It includes metrics for demand generation, audience strategy, engagement intensity, and long-term growth potential [11][12] Future Outlook - The GAIN model is expected to facilitate a paradigm shift for brands from short-term gains to long-term value management, enhancing their competitive edge in the market [15][16] - With advancements in AI and big data, user value management will become more intelligent and precise, allowing brands to better understand user needs and optimize engagement [16]

Core Insights - The health management market is experiencing a paradox where traditional methods are limited in addressing chronic and complex health issues, while emerging concepts like probiotics face skepticism due to unclear efficacy and competition among various products [1][4] - MGBlab is positioned as an innovative leader in the microbiome medical field, aiming to shift the focus from merely alleviating symptoms to restoring ecological balance through advanced microbial medical technology [1][2] Industry Overview - The industry is currently caught between superficial interventions and a need for systemic health solutions, with MGBlab striving to redefine health management through a comprehensive approach [1][9] - MGBlab's unique "technology triangle" integrates localized probiotic development, AI-assisted formulation, and a closed-loop command chain for health interventions, marking a departure from traditional one-size-fits-all probiotic solutions [2][4] Product Development - MGBlab has established a rigorous standard for probiotics, emphasizing the verification of synergistic effects and clinical outcomes, thus prioritizing efficacy over marketing hype [4][5] - The company has developed over 40 core patents covering the entire chain from strain development to effect validation, solidifying its reputation as a "microbial medical innovation engine" [4][5] Clinical Research - Recent clinical studies at Anhui Medical University demonstrated significant growth improvements in children using the BL-11 strain derived from Chinese breast milk, with an average height increase of 2.23 cm over three months [5][7] - The BL-11 strain has been clinically validated to enhance the gut-bone axis, promoting the production of key growth factors, thereby supporting children's development [7][8] Technological Advancements - MGBlab's digital microbiome data platform ensures the optimal replication of breast milk bacterial environments, maintaining high viability of the BL-11 strain during production [8][9] - The company has successfully tested its strains in extreme conditions, such as space, demonstrating over 95% survival rates and stability, setting a new benchmark in the industry [10][12] Future Directions - MGBlab aligns with national health initiatives aimed at improving child nutrition and health services, advocating for a paradigm shift from disease treatment to proactive health ecosystem restoration [9][12] - The company's approach integrates extensive clinical data and AI to transition from reactive treatment to preventive health management, making microbiome interventions more accessible [9][12]

Group 1 - The forum on the development of new automotive productivity was held in Chongqing, emphasizing the importance of user service and innovation in the automotive industry [1] - The chairman of Seres, Zhang Xinghai, highlighted that new energy vehicles (NEVs) align with the characteristics of new productivity, which include high technology, high efficiency, and high quality [3] - Seres has developed a "smart safety" technology system with over 340 safety features, focusing on user safety as a core principle [3] Group 2 - Seres has partnered with Huawei since 2021 to integrate the automotive and ICT industries, leading to successful high-end models like the Wenjie M9 [5] - The company has integrated 100 first-tier suppliers into its supply chain, including 20 world-class enterprises, to enhance its production capabilities [6] - The establishment of CATL's first base in Chongqing at Seres' super factory will produce high-end batteries specifically for Wenjie vehicles [6]

Group 1 - Astaxanthin, derived from Haematococcus pluvialis, is recognized as one of the strongest natural antioxidants and has garnered significant attention for its health benefits [1] - Research conducted by a team from Xiamen Health Medical Big Data Center indicates that astaxanthin can improve insulin resistance in type 2 diabetes mellitus (T2DM) through various mechanisms [3][4] - The study highlights that astaxanthin lowers fasting blood glucose levels and enhances insulin sensitivity while reducing inflammation by inhibiting TNF-α and IL-6 expression [3][5] Group 2 - The market for astaxanthin is experiencing robust growth, driven by multiple studies confirming its health benefits, particularly in diabetes management [7] - Green A Bio, a pioneer in the industrialization of Haematococcus pluvialis astaxanthin in China, has achieved significant breakthroughs in astaxanthin production technology and holds patents in this field [7] - The company has launched a range of high-quality products, including Red A Astaxanthin and Frozen Age Astaxanthin, which support various health benefits such as antioxidant effects, anti-inflammatory properties, and improved glucose metabolism [7] Group 3 - Diabetes, characterized by high blood sugar levels, is a chronic metabolic disease with increasing prevalence [8] - The potential of astaxanthin in diabetes prevention and treatment is becoming more evident as scientific research progresses [8] - There is optimism that astaxanthin will play a significant role in various health domains, contributing to human health advancements [8]

2025年7月29日，上海市建筑行业第一届优质供应商名录发布会暨全产业链对接大会在上海隆重举行。 上海市房地产行业协会联合三家权威行业协会搭建平台整合资源，经过三重严格筛选，最终从众多企业 中确定105家优质单位入选首份供应商名录。涵盖设计单位、施工单位和材料单位三大类，为上海"好房 子"建设、城市更新和绿色转型注入全新动能。 据大会发布信息，本次评选最终确定优质设计单位24家、施工单位7家、材料单位（家电类）25家、材 料单位（装饰材料）49家。其中装饰材料类占据近半数份额，体现了基础建材在建筑品质中的关键地 位，105家入选单位将成为上海建筑行业高质量发展的核心力量，为上海建筑行业的高质量发展提供切 实支持和保障。 在本次入选的优质供应商中，上海爱迪技术发展有限公司凭借其在建筑粘贴材料领域的技术创新和卓越 品质荣获"装饰材料类优质供应商"称号。自1993年创立以来，爱迪技术已深耕建筑材料及应用技术领域 32年。公司始终秉持"持续创新，优质产品，让建筑更完美"的企业使命。爱迪公司解决了石材、人造石 材、玻化砖的泛碱、水斑、空鼓、脱落、开裂等行业顽固性质量问题。 上海爱迪技术发展有限公司在本次评选中凭借其革命 ...

Company Overview - Hefei Zero Point Robot Co., Ltd. has completed angel financing rounds totaling over 100 million yuan, with funds primarily allocated for technological breakthroughs, production acceleration, and ecological layout [1][4] - The company was established in January 2025, with core members from Tsinghua University's AI & Robot Intelligent Robotics Laboratory, including several former employees from major tech firms like ByteDance and Baidu [1] Product Development - Within six months of its establishment, Zero Point Robot has developed a comprehensive product line, including embodied intelligent hardware and software solutions, as well as commercial service scenario solutions [1][3] - In May 2025, the company launched the Zerith-V0 model and Zerith-H1 humanoid robot, providing integrated solutions for commercial service scenarios, becoming the first in China to achieve long-sequence multi-task operations in specific scenarios [2][3] Market Potential - The embodied intelligent robot market in China is projected to reach 5.295 billion yuan by 2025, accounting for approximately 27% of the global market, while the humanoid robot market is expected to reach 8.239 billion yuan, representing about 50% of the global market [2] - The transition from the "technology validation phase" to the "scale commercialization phase" for humanoid robots is anticipated to accelerate, driven by practical implementations from companies like Zero Point Robot [2] Financial Performance - Zero Point Robot has secured orders worth several tens of millions of yuan, with total intended orders nearing 100 million yuan, covering sectors such as research and education, data centers, hotel services, and entertainment exhibitions [3] Future Plans - The funds raised will be used to enhance the "technology breakthrough-production capacity-ecological collaboration" framework, focusing on algorithm development for complex scenarios, accelerating the construction of flexible production lines, and creating a data hub for the embodied intelligence industry [4] - The company aims to deliver over 500 robots of various models by the end of the year, emphasizing deep applications in commercial service scenarios [4] Strategic Vision - The founder of Zero Point Robot stated that embodied intelligence aims to reshape productivity rather than replace humans, with a goal to reduce the cost of using robots to 60% of human labor within three years [5] - Investors highlight the company's innovative breakthroughs and its ability to implement technology in real-world scenarios, positioning it as a leader in the embodied intelligence sector [6][7][8]

Core Viewpoint - NYO3 has launched its "Anti-Aging Trio" series in Shanghai, focusing on scientific anti-aging solutions for various consumer needs, including skin and ovarian health [1][3]. Group 1: Product Overview - The "Anti-Aging Trio" includes three key products: Ageless Deep Sea Collagen Peptide, Ageless Skin Care Pills, and Ageless Noble Nest Pills, each targeting specific anti-aging needs [3]. - Ageless Deep Sea Collagen Peptide has increased its collagen tripeptide content from 5500mg to 6100mg, achieving three times the market standard, with a low caloric value of 31.3 kcal per bottle [3]. - Ageless Skin Care Pills utilize a phospholipid cell-level delivery technology, achieving a 98% absorption rate, with clinical trials showing significant improvements in skin texture and appearance over 28 days [3][9]. - Ageless Noble Nest Pills combine phospholipid Omega-3 and inositol to enhance endocrine regulation and ovarian cell energy activation [3]. Group 2: Technological Leadership - NYO3 leverages advanced Norwegian anti-aging research and collaborates with the NO-AGE research center to develop high-end oral anti-aging products [5]. - The company emphasizes technological innovation as its core competitive advantage, utilizing a unique phospholipid delivery system to enhance absorption rates to 98% [5]. - Ageless products promise visible results within 30 days, addressing common consumer concerns about high costs and slow effects in the oral anti-aging market [5]. Group 3: Market Recognition - NYO3 has gained recognition as the "No. 1 Anti-Aging Brand in Northern Europe," supported by clinical data from NO-AGE and real-world testing conducted in collaboration with a reputable testing agency [7]. - The Ageless product line has achieved significant market success, with the Skin Care Pills topping the Tmall International oral beauty rankings shortly after launch [9]. - The brand's commitment to quality and innovation has earned it accolades, including the prestigious Monte Award in the dietary nutrition sector [9].

白酒版图上，一场围绕"低度"的竞速正迅速升温。越来越多的酒企开始推出低度白酒产品，试图打开新 的消费场景、触达更广的人群。低度白酒，正从边缘品类转变为新的增量引擎。 在这条如今热闹非凡的赛道上，率先入局并取得领先地位的，是泸州老窖（000568）旗下的超高端白酒 品牌国窖1573。 在所有白酒香型中，浓香型白酒依赖于泥窖窖池发酵，且持续使用越久的窖池酿出的原酒品质越高。究 其原因，当泥窖窖池持续使用时间越长，窖池窖泥的优势微生物菌群越突出，特别是百年以上的老窖 池，窖泥中的酿酒微生物经过长期驯化富集，酿出的酒体窖香、粮香、陈香等复合香气饱满浓郁，主体 香突出，从而在降度之后依然能保持"低而不淡"。 国窖1573早在2001年就推出了38%vol，通过二十余年的消费培育，凭借卓越的品质表现与动销能力， 成为全国首先破百亿的低度白酒大单品，完成了从消费培育到市场引爆。 今天的白酒低度化趋势，某种程度上，正是国窖1573率先"跑出来"的结果。 趋势将至，有人早已在场 近年来，随着年轻群体接棒消费主力，白酒的饮用习惯正在悄然改变。"轻饮""微醺""不醉也尽兴"成为 新主张，低度酒顺势而起，成为众多酒企竞相布局的新蓝海 ...